



SurModics Expands Protein-Free Stabilizer Line with AP Option

July 28, 2014

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jul. 28, 2014-- SurModics IVD, Inc., a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for [in vitro diagnostic assay components](#), is introducing StabilZyme[®] Protein-Free AP Stabilizer at the American Association for Clinical Chemistry meeting currently taking place in Chicago.

"Protein interference is a frequent concern, particularly as more sensitive assays are developed," says Drew Pauly, Director of Product Development, SurModics IVD. "Proteins used in many stabilizers can lead to increased non-specific binding due to protein interference. There is a need for a protein-free stabilizer for alkaline phosphatase conjugates that delivers equivalent performance to protein-containing stabilizers, including those with BSA (bovine serum albumin). This new StabilZyme protein-free stabilizer achieves that goal."

The new stabilizer eliminates protein-related interference and cross-reactivity. It also offers excellent performance. The retained activity of StabilZyme Protein-Free AP Stabilizer is comparable to its protein-containing counterpart—StabilZyme AP Conjugate Stabilizer—and superior to other protein-free/BSA-free stabilizers on the market. It performs across all species of antibodies, even at low concentrations.

AACC attendees can learn more by visiting the SurModics IVD Booth #1938. AACC is the world's largest laboratory medicine exposition, with 20,000 attendees.

SurModics IVD offers a full range of innovative solutions, including custom formulations, for the *in vitro* diagnostics industry. To learn more, visit our website (www.surmodics.com/ivd), or contact customer service (952-500-7200 or orders@surmodics.com). More than 900 IVD products are available for online ordering at shop.surmodics.com.

About SurModics, Inc.

SurModics' mission is to exceed our customers' expectations and enhance the wellbeing of patients by providing the world's foremost, innovative surface modification technologies and *in vitro* diagnostic chemical components. The Company partners with the world's leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include (i) surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities, and (ii) components for *in vitro* diagnostic tests and microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For more information about the Company, visit <http://www.surmodics.com>. The content of SurModics' website is not part of this release or part of any filings the Company makes with the SEC.

SurModics and *StabilZyme* are registered trademarks of SurModics, Inc. and/or its affiliates.

Source: SurModics, Inc.

SurModics, Inc.

Andy LaFrence, 952-500-7000

Vice President Finance and Chief Financial Officer